To read the full story, subscribe or sign in.

Gennbio licenses in two immunosuppressants valued up to $164M from Genexine

Jan. 14, 2020

Gennbio Co. Ltd. has signed an agreement with fellow Korean biotech Genexine Inc. to in-license two immunosuppressant drug candidates called GX-P1 (PD-L1 hyfc) and BSF-110 (PD-L1-hyFc-1L10m).

BioWorld Asia Deals and M&A Immune Asia-Pacific

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld Asia

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Today's news in brief

BioWorld

BioWorld briefs for August 3.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for Aug. 3.

Business people with hands atop a digital globe

Mologic acquired by philanthropists to become social enterprise

BioWorld MedTech

LONDON – U.K. rapid diagnostics specialist Mologic Ltd. has been acquired by a group of philanthropists led by George Soros’ Economic Development Fund and the...